USA - engelsk - NLM (National Library of Medicine)

sanofi-aventis u.s. llc - desmopressin acetate (unii: xb13hyu18u) (desmopressin - unii:enr1llb0fp) - desmopressin acetate 4 ug in 1 ml

USA - engelsk - NLM (National Library of Medicine)

sanofi-aventis u.s. llc - riluzole (unii: 7lj087rs6f) (riluzole - unii:7lj087rs6f) - riluzole 50 mg

USA - engelsk - NLM (National Library of Medicine)

sanofi-aventis u.s. llc - primaquine phosphate (unii: h0982hf78b) (primaquine - unii:mvr3634gx1) - primaquine 15 mg - primaquine phosphate is indicated for the radical cure (prevention of relapse) of vivax malaria. severe glucose-6-phosphate dehydrogenase (g6pd) deficiency (see warnings). pregnant women (see warnings, usage in pregnancy). primaquine phosphate is contraindicated in acutely ill patients suffering from systemic disease manifested by tendency to granulocytopenia, such as rheumatoid arthritis and lupus erythematosus. the drug is also contraindicated in patients receiving concurrently other potentially hemolytic drugs or depressants of myeloid elements of the bone marrow. because quinacrine hydrochloride appears to potentiate the toxicity of antimalarial compounds which are structurally related to primaquine, the use of quinacrine in patients receiving primaquine is contraindicated. similarly, primaquine should not be administered to patients who have received quinacrine recently, as toxicity is increased.

USA - engelsk - NLM (National Library of Medicine)

sanofi-aventis u.s. llc - dolasetron mesylate (unii: u3c8e5bwkr) (dolasetron - unii:82wi2l7q6e) - dolasetron mesylate 12.5 mg in 0.625 ml

USA - engelsk - NLM (National Library of Medicine)

sanofi-aventis u.s. llc - levocetirizine dihydrochloride (unii: sod6a38aga) (levocetirizine - unii:6u5ea9rt2o) - levocetirizine dihydrochloride 5 mg

USA - engelsk - NLM (National Library of Medicine)

sanofi-aventis u.s. llc - rifampin (unii: vjt6j7r4tr) (rifampin - unii:vjt6j7r4tr), isoniazid (unii: v83o1voz8l) (isoniazid - unii:v83o1voz8l) - rifampin 300 mg - in the treatment of tuberculosis, the small number of resistant cells present within large populations of susceptible cells can rapidly become the predominant type. since resistance can emerge rapidly, susceptibility tests should be performed in the event of persistent positive cultures during the course of treatment. bacteriologic smears or cultures should be obtained before the start of therapy to confirm the susceptibility of the organism to rifampin and isoniazid, and they should be repeated throughout therapy to monitor response to the treatment. if test results show resistance to any of the components of rifamate and the patient is not responding to therapy, the drug regimen should be modified. rifamate is indicated for pulmonary tuberculosis in which organisms are susceptible, and when the patient has been titrated on the individual components and it has therefore been established that this fixed dosage is therapeutically effective. this fixed-dosage combination drug is not recommended for initial ther

USA - engelsk - NLM (National Library of Medicine)

sanofi-aventis u.s. llc - methenamine hippurate (unii: m329791l57) (methenamine - unii:j50oix95qv) - methenamine hippurate 1 g

USA - engelsk - NLM (National Library of Medicine)

sanofi-aventis u.s. llc - nilutamide (unii: 51g6i8b902) (nilutamide - unii:51g6i8b902) - nilutamide 150 mg

USA - engelsk - NLM (National Library of Medicine)

sanofi-aventis u.s. llc - levocetirizine dihydrochloride (unii: sod6a38aga) (levocetirizine - unii:6u5ea9rt2o) - levocetirizine dihydrochloride 5 mg - xyzal is indicated for the relief of symptoms associated with perennial allergic rhinitis in children 6 months to 2 years of age. xyzal is indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 months of age and older. the use of xyzal is contraindicated in: patients with known hypersensitivity to levocetirizine or any of the ingredients of xyzal, or to cetirizine. observed reactions range from urticaria to anaphylaxis [see adverse reactions (6.2)] . patients with end-stage renal disease (clcr <10 ml/min) and patients undergoing hemodialysis children 6 months to 11 years of age with impaired renal function risk summary available data from published literature and postmarketing experience with levocetirizine use in pregnant women are insufficient to identify any drug-associated risks of miscarriage, birth defects, or adverse maternal or fetal outcomes. in animal reproduction studies, there was no evidence of fetal harm with administration

USA - engelsk - NLM (National Library of Medicine)

sanofi-aventis u.s. llc - milrinone lactate (unii: 9k8xr81mo8) (milrinone - unii:ju9yax04c7) - 200 ug in 1 ml